**Contents**

**Highlights of This Issue** 3999

**SPECIAL FEATURES**

**CCR Translations**

4001  How to Develop Treatments for Biologically Heterogeneous "Diseases"  
Richard M. Simon  
See article p. 4004

**Statistics in Clinical Cancer Research**

4004  Design of a Phase III Clinical Trial with Prospective Biomarker Validation: SWOG S0819  
Mary W. Redman, John J. Crowley, Roy S. Herbst, Fred R. Hirsch, and David R. Gandara  
See commentary p. 4001

**Molecular Pathways**

4013  Molecular Pathways: Targeting Phosphoinositide 3-Kinase p110-Delta in Chronic Lymphocytic Leukemia  
Sarah E.M. Herman and Amy J. Johnson

4019  Molecular Pathways: Involving Microenvironment Damage Responses in Cancer Therapy Resistance  
Yu Sun and Peter S. Nelson

**HUMAN CANCER BIOLOGY**

4026  Molecular Profiling Reveals Low- and High-Grade Forms of Primary Melanoma  

---

**CANCER THERAPY: PRECLINICAL**

4037  Galectin-1 Promotes Lung Cancer Progression and Chemoresistance by Upregulating p38 MAPK, ERK, and Cyclooxygenase-2  

4048  EZH2-Regulated DAB2IP Is a Medulloblastoma Tumor Suppressor and a Positive Marker for Survival  
Michiel Smits, Sjoerd van Rijn, Esther Hulman, Dennis Biesmans, Damir G. van Vuurden, Marcel Kool, Christine Haberler, Eleonora Aronica, W. Peter Vandertop, David P. Noske, and Thomas Würdinger

4059  Overexpression of GOLPH3 Promotes Proliferation and Tumorigenicity in Breast Cancer via Suppression of the FOXO1 Transcription Factor  
Zhaolei Zeng, Huanxin Lin, Xiaohui Zhao, Guanglin Liu, Xi Wang, Ruibhua Xu, Kun Chen, Jun Li, and Libing Song

4070  Inhibition of Histone Deacetylation Potentiates the Evolution of Acquired Temozolomide Resistance Linked to MGMT Upregulation in Glioblastoma Xenografts  

4080  IGKV3 Proteins as Candidate "Off-the-Shelf" Vaccines for Kappa-Light Chain–Restricted B-Cell Non-Hodgkin Lymphomas  
Debora Martorelli, Massimo Guidoboni, Vali De Re, Elena Muraro, Riccardo Turrini, Anna Merlo, Elisa Pasini, Laura Cagliari, Luca Romagnoli, Michele Spina, Roberta Mortarini, Daniela Gasparotto, Mario Mazzucato, Antonino Carbone, Antonio Rosato, Andrea Anichini, and Riccardo Dolcetti
Functional Analysis of the ATM-p53-p21 Pathway in the LRF CLL4 Trial: Blockade at the Level of p21 Is Associated with Short Response Duration

Ke Lin, Janet Adamson, Gillian G. Johnson, Anthony Carter, Melanie Oates, Rachel Wade, Sue Richards, David Gonzalez, Estella Matutes, Claire Dearden, David G. Oscier, Daniel Catovsky, and Andrew R. Pettitt

4201

TP53 Genomic Status Regulates Sensitivity of Gastric Cancer Cells to the Histone Methylation Inhibitor 3-Deazaneplanocin A (DZNep)

Lai Ling Cheng, Yoko Itahana, Zheng Deng Lei, Na-Yu Chia, Yonghui Wu, Yingnan Yu, Shen Li Zhang, Aye Aye Thike, Anuradha Pandey, Steve Rozen, Pieter Mathijs Voorhoeve, Qiang Yu, Puay Hoon Tan, Boom Huat Bay, Koji Itahana, and Patrick Tan

4201

LETTERS TO THE EDITOR

Lifetime Cancer Risks of PTEN Mutation Carriers—Letter
Molly S. Daniels, Thereasa Rich, Scott Weissman, and Robert Pilarski

Life Time Cancer Risks of PTEN Mutation Carriers—Response
Min-Han Tan, Jessica Mester, and Charis Eng

4213

CORRECTIONS

Correction: New Strategies in Squamous Cell Carcinoma of the Lung: Identification of Tumor Drivers to Personalize Therapy

Correction: MicroRNA-148a Suppresses Tumor Cell Invasion and Metastasis by Downregulating ROCK1 in Gastric Cancer

4215

4216

ABOUT THE COVER

The recently discovered recurrent ERG rearrangement is highly specific for prostate cancer. There are significant associations of ERG rearrangement in preoperative biopsies with pelvic lymph node metastasis for patients with prostate cancer. The fluorescence in situ hybridization image shows representative nuclei of a prostate cancer gland. One yellow/one green/one red in a nucleus represents abnormal signal patterns indicative of an ERG rearrangement. For details, please see the article by Gao and colleagues on page 4163 of this issue.